Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Kathleen A, Dorritie"'
Autor:
Kevin Quann, Konstantinos Lontos, Alison Sehgal, Anastasios Raptis, Annie Im, Robert L. Redner, Kathleen A. Dorritie, Mounzer Agha, Jing-Zhou Hou, Rafic Farah, James Rossetti, Daniel P. Normolle, Theresa L. Whiteside, Yen-Michael Sheng Hsu, Michael Boyiadzis
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/1352c6751639460db757ad5297580943
Autor:
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Publikováno v:
Journal of Clinical Oncology. 41:2594-2606
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1ebedb9cdef4e30b7e8b0e20978feb3
https://doi.org/10.1200/jco.22.01797
https://doi.org/10.1200/jco.22.01797
Autor:
Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Nidhi Aggarwal, Melissa Saul, Michael Boyiadzis, Nathanael G. Bailey
Publikováno v:
Leukemia & Lymphoma. 64:750-752
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ab86023c45e19f022f46d52542c7767
https://doi.org/10.1080/10428194.2023.2172981
https://doi.org/10.1080/10428194.2023.2172981
Autor:
Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Nidhi Aggarwal, Melissa Saul, William Gooding, Michael Boyiadzis
Publikováno v:
Leukemia & Lymphoma. 63:3257-3260
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e0293238f553b5c5e88284a47c3473
https://doi.org/10.1080/10428194.2022.2118532
https://doi.org/10.1080/10428194.2022.2118532
Autor:
Yu Shen, Marina Konopleva, Warren M. Kati, Keith F. McDaniel, Daniel H. Albert, Michael Boyiadzis, Kathleen A. Dorritie, Neal C. Goodwin, Jenny Rowe, Terrance J. Magoc, Sriram S. Shanmugavelandy, Gaurav Mehta, Debra C. Ferguson, Lina Han, Antonio Cavazos, Qi Zhang, Tamar Uziel, Paul Hessler, Weiguo Feng, Zheng Zha, Xin Lu, Lloyd T. Lam, Vinitha M. Kuruvilla, Emily J. Faivre, Richard J. Bellin, Joshua P. Plotnik, Mai H. Bui, Xiaoli Huang, Xiaoyu Lin, Tianyu Cai, Lu Zhang
Figure S2. ABBV-744 retains strong transcription regulatory activities in AML cells and it did not alter the baseline expression of representative IFN-r or PMA responsive genes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393d469bbbdbf0d0186b629a919bb58b
https://doi.org/10.1158/1535-7163.22521673.v1
https://doi.org/10.1158/1535-7163.22521673.v1
Autor:
Yu Shen, Marina Konopleva, Warren M. Kati, Keith F. McDaniel, Daniel H. Albert, Michael Boyiadzis, Kathleen A. Dorritie, Neal C. Goodwin, Jenny Rowe, Terrance J. Magoc, Sriram S. Shanmugavelandy, Gaurav Mehta, Debra C. Ferguson, Lina Han, Antonio Cavazos, Qi Zhang, Tamar Uziel, Paul Hessler, Weiguo Feng, Zheng Zha, Xin Lu, Lloyd T. Lam, Vinitha M. Kuruvilla, Emily J. Faivre, Richard J. Bellin, Joshua P. Plotnik, Mai H. Bui, Xiaoli Huang, Xiaoyu Lin, Tianyu Cai, Lu Zhang
Primary patient sample information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::282ab3dc5a5370970baa604506670681
https://doi.org/10.1158/1535-7163.22521655.v1
https://doi.org/10.1158/1535-7163.22521655.v1
Autor:
Yu Shen, Marina Konopleva, Warren M. Kati, Keith F. McDaniel, Daniel H. Albert, Michael Boyiadzis, Kathleen A. Dorritie, Neal C. Goodwin, Jenny Rowe, Terrance J. Magoc, Sriram S. Shanmugavelandy, Gaurav Mehta, Debra C. Ferguson, Lina Han, Antonio Cavazos, Qi Zhang, Tamar Uziel, Paul Hessler, Weiguo Feng, Zheng Zha, Xin Lu, Lloyd T. Lam, Vinitha M. Kuruvilla, Emily J. Faivre, Richard J. Bellin, Joshua P. Plotnik, Mai H. Bui, Xiaoli Huang, Xiaoyu Lin, Tianyu Cai, Lu Zhang
Supplementary figure and table legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92caa8459e59b7bf1287845739d1ee4a
https://doi.org/10.1158/1535-7163.22521658.v1
https://doi.org/10.1158/1535-7163.22521658.v1
Autor:
Yu Shen, Marina Konopleva, Warren M. Kati, Keith F. McDaniel, Daniel H. Albert, Michael Boyiadzis, Kathleen A. Dorritie, Neal C. Goodwin, Jenny Rowe, Terrance J. Magoc, Sriram S. Shanmugavelandy, Gaurav Mehta, Debra C. Ferguson, Lina Han, Antonio Cavazos, Qi Zhang, Tamar Uziel, Paul Hessler, Weiguo Feng, Zheng Zha, Xin Lu, Lloyd T. Lam, Vinitha M. Kuruvilla, Emily J. Faivre, Richard J. Bellin, Joshua P. Plotnik, Mai H. Bui, Xiaoli Huang, Xiaoyu Lin, Tianyu Cai, Lu Zhang
Dual bromodomain BET inhibitors that bind with similar affinities to the first and second bromodomains across BRD2, BRD3, BRD4, and BRDT have displayed modest activity as monotherapy in clinical trials. Thrombocytopenia, closely followed by symptoms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d00f3fe37fd40d5b4caa87153f1a3bc
https://doi.org/10.1158/1535-7163.c.6543097.v1
https://doi.org/10.1158/1535-7163.c.6543097.v1
Autor:
Daniel H, Albert, Neal C, Goodwin, Angela M, Davies, Jenny, Rowe, Gerold, Feuer, Michael, Boyiadzis, Kathleen A, Dorritie, Maria, Mancini, Regina, Gandour-Edwards, Brian A, Jonas, Gautam, Borthakur, Ibrahim, Aldoss, David A, Rizzieri, Olatoyosi, Odenike, Thomas, Prebet, Sanjana, Singh, Relja, Popovic, Y U, Shen, Keith F, McDaniel, Warren M, Kati, Dimple A, Modi, Monica, Motwani, Johannes E, Wolff, David J, Frost
Publikováno v:
In vivo (Athens, Greece), vol 36, iss 4
In Vivo
In Vivo
Background/Aim: The therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, although as of yet, no BET-targeting agent has achie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b4eba30d71a0c94f22fec4754a6d96c
https://escholarship.org/uc/item/8v66m4jc
https://escholarship.org/uc/item/8v66m4jc
Autor:
Donna M. Posluszny, Dana H. Bovbjerg, Karen L. Syrjala, Mounzer Agha, Rafic Farah, Jing-Zhou Hou, Anastasios Raptis, Annie P. Im, Kathleen A. Dorritie, Michael M. Boyiadzis, Mary Amanda Dew
Publikováno v:
Transplant Cell Ther
Allogeneic hematopoietic cell transplantation (HCT) requires a complex, multicomponent medical regimen after hospital discharge. Patients must manage multiple medications; care for their catheter; minimize exposure to sources of potential infection;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::661b0c1d8c20521a7990ccc534d3f015
https://europepmc.org/articles/PMC9004486/
https://europepmc.org/articles/PMC9004486/